REVITOPE ONCOLOGY
Dead / Abandoned — Abandoned — no statement of use filed (as of 01 Oct 2025)
What this means for you
This application is over — abandoned 01 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90430529
- Mark type
- Stylized text
- Filed
- 30 Dec 2020
- Published for opposition
- 19 Oct 2021
- Abandoned
- 01 Oct 2025
- Attorney of record
- Monica Riva Talley
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals, namely, immunotherapies for the treatment of cancer and oncological conditions; oncological preparations, namely, pharmaceutical products for the detection, prevention, and treatment of cancer; anti-cancer preparations; biological preparations for the treatment of cancer and oncological conditions; pharmaceutical products for the prevention and treatment of cancer and oncological conditions
Owner
- Revitope Oncology, Inc., Cambridge, MA, US
- Revitope Oncology, Inc., Cambridge, MA, US
Prosecution history
- 01 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 01 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 14 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Jun 2024 — SOU EXTENSION 5 GRANTED
- 14 Jun 2024 — SOU EXTENSION 5 FILED
- 14 Jun 2024 — SOU TEAS EXTENSION RECEIVED
- 16 Dec 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Dec 2023 — SOU EXTENSION 4 GRANTED
- 14 Dec 2023 — SOU EXTENSION 4 FILED
- 14 Dec 2023 — SOU TEAS EXTENSION RECEIVED
- 16 Jun 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Jun 2023 — SOU EXTENSION 3 GRANTED
- 14 Jun 2023 — SOU EXTENSION 3 FILED
- 14 Jun 2023 — SOU TEAS EXTENSION RECEIVED
- 16 Dec 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED